Depression and heart failure: the lonely comorbidity

Area of Science:

• Cardiology
• Psychiatry
• Comorbidity Research

Background:

• Depression affects up to 30% of heart failure (HF) patients, significantly worsening quality of life and clinical outcomes.
• Shared pathophysiological mechanisms and risk factors link depression and HF, including inflammation, neuroendocrine dysfunction, and behavioral factors.

Purpose of the Study:

• To review the epidemiology and pathophysiology of depression in HF patients.
• To discuss current and emerging diagnostic and therapeutic strategies for managing comorbid depression in HF.

Main Methods:

• Literature review examining the intersection of depression and HF.
• Analysis of shared mechanisms, risk factors, and treatment modalities.
• Discussion of current guidelines and future research directions.

Main Results:

• Depression is a prevalent and detrimental comorbidity in HF patients, associated with poorer prognosis.
• Established treatments like SSRIs show safety but lack proven superiority over placebo in HF.
• Novel therapies including NMDA receptor antagonists and rTMS show promise for future depression management in HF.

Conclusions:

• Effective screening and diagnosis are crucial for managing depression in HF.
• While current treatments have limitations, emerging therapies offer new hope for improving outcomes in HF patients with depression.
• Further research is needed to validate new technologies and therapeutic approaches.